Shares of Venus Remedies surged 4% after the company received a Good Manufacturing Practice (GMP) certification from the Ministry of Health of Moldova for its carbapenem antibiotic facility. This certification positions Venus Remedies to strengthen its presence in the Eastern European market.
With GMP approval, the company ensures the delivery of high-quality, effective, and reliable antibiotics to healthcare providers and patients across the region. Investors view this milestone as a step toward expanding global market reach and enhancing growth prospects.
Venus Remedies shares opened at ₹309.90 today, reaching a high of ₹324.00 and a low of ₹306.40. The stock remains below its 52-week high of ₹430.00 but above its 52-week low of ₹281.10.
As of 1:09 p.m., Venus Remedies shares were trading 4.50% higher at Rs 324.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
